Pfizer Inc. has acquired FoldRx Pharmaceuticals, Inc., making the biotech company a wholly owned subsidiary. The deal integrates FoldRx’s expertise into Pfizer’s portfolio, though specific terms or strategic applications remain unstated in the announcement.
Pfizer Inc. has agreed to acquire FoldRx Pharmaceuticals, a privately held company specializing in drug discovery and clinical development. The deal combines Pfizer’s resources with FoldRx’s expertise in protein-folding therapeutics. Terms of the acquisition were not disclosed in the announcement.
FoldRx Pharmaceuticals raises **$29 million** to advance **tafamidis**, a therapy for **TTR amyloid polyneuropathy (ATTR-PN)**, a genetic neurodegenerative disease. The company reports **positive pivotal trial results** for tafamidis, supporting its potential as a disease-modifying treatment. Novo Ventures and Morgenthaler Ventures join as new investors in the financing round.